{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:49:38Z","timestamp":1774554578815,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Federal Ministry for Health and Social Services"},{"name":"EU project CHAIN"},{"name":"Heinz-Ansmann-Stiftung for AIDS Research"},{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To quantify virologic failure (VF), identify predictors, characterize resistance patterns at failure, and evaluate time to resuppression in the RESINA cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ART-na\u00efve adults initiating ART in 2001\u20132024 were followed. VF was defined as at least one HIV-1 RNA\u2009&gt;\u2009200 copies\/mL after suppression or\u2009\u2265\u20090.5-log\u2081\u2080 rebound. Participants were grouped by treatment era (2001\u20132007, 2008\u20132013,\u2009\u2265\u20092014), reflecting availability of drug classes. Genotypes at baseline and VF were interpreted using the HIV-GRADE algorithm. Predictors of VF were assessed with logistic regression; time to resuppression (&lt;\u200950 copies\/mL) after first VF with Cox models and Kaplan\u2013Meier plots.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 5136 participants, 139 (2.7%) had VF; rates declined across eras (4.7%, 2.6%, 1.7%). Independent predictors were injection-drug use (OR 1.74), CD4\u2009&lt;\u2009200\/\u00b5L (OR 2.32), and ART start in 2001\u20132007 (OR 1.95); MSM acquisition was protective (OR 0.32). At failure, 36 patients showed resistance, often multiclass (61%); INSTI resistance was rare (n\u2009=\u20095). After first VF, 122\/139 cases resuppressed (median 147\u00a0days). Male sex predicted faster resuppression (HR 1.81); higher failure VL trended to slower resuppression (HR 0.84 per log\u2081\u2080). INSTI-based switches consistently achieved resuppression in descriptive analyses and were not associated with multiclass resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>VF was uncommon and declined over time, reflecting improved regimen potency and tolerability. Failures were associated with late presentation and IDU, consistent with adherence barriers. Resistance often involved multiple classes, while INSTI resistance remained infrequent. Early, genotype-guided optimization, preferably to INSTI-based therapy, combined with targeted adherence support may improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02713-7","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:03:15Z","timestamp":1765958595000},"page":"817-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIV-1 virologic failure in the RESINA cohort: lessons from two decades of real-world data"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-504X","authenticated-orcid":false,"given":"Smaranda","family":"Gliga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Killer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"H\u00fcttig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lila","family":"Haberl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Heger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"B\u00fcch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Oette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heribert","family":"Knechten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Sch\u00fcbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Esser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schneewei\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazifa","family":"Qurishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"R\u00f6mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn-Erik Ole","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the RESINA Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2713_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1089\/AID.2021.0233","volume":"38","author":"M Narv\u00e1ez","year":"2022","unstructured":"Narv\u00e1ez M, Lins-Kusterer L, Valdelamar-Jim\u00e9nez J, Brites C. Quality of life and antiretroviral therapy adherence: a cross-sectional study in Colombia. AIDS Res Hum Retroviruses. 2022;38:660\u20139. https:\/\/doi.org\/10.1089\/AID.2021.0233.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2713_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1056\/NEJM200103153441108","volume":"344","author":"KA Freedberg","year":"2001","unstructured":"Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824\u201331. https:\/\/doi.org\/10.1056\/NEJM200103153441108.","journal-title":"N Engl J Med"},{"key":"2713_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","volume":"83","author":"P Cahn","year":"2020","unstructured":"Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment\u2013naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83:310\u20138. https:\/\/doi.org\/10.1097\/QAI.0000000000002275.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2713_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(12)61853-4.","journal-title":"Lancet"},{"key":"2713_CR5","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. September 12, 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/virologic-failure"},{"key":"2713_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/0003-4819-131-2-199907200-00002","volume":"131","author":"GM Lucas","year":"1999","unstructured":"Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81\u20137. https:\/\/doi.org\/10.7326\/0003-4819-131-2-199907200-00002.","journal-title":"Ann Intern Med"},{"key":"2713_CR7","unstructured":"Management of virologic failure. https:\/\/www.hiv.uw.edu\/go\/antiretroviral-therapy\/evaluation-management-virologic-failure\/core-concept\/all (2025). Accessed 24 Apr 2025"},{"key":"2713_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"MW Tang","year":"2012","unstructured":"Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72:e1-25. https:\/\/doi.org\/10.2165\/11633630-000000000-00000.","journal-title":"Drugs"},{"issue":"2","key":"2713_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00042560-200102010-00008","volume":"26","author":"AL Moore","year":"2001","unstructured":"Moore AL, Mocroft A, Madge S, Devereux H, Wilson D, Phillips AN, et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr. 2001;26(2):159\u201363. https:\/\/doi.org\/10.1097\/00042560-200102010-00008.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2713_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1089\/aid.2019.0096","volume":"35","author":"G Wu","year":"2019","unstructured":"Wu G, Zhou C, Zhang X, Zhang W, Lu R, Ouyang L, et al. Higher risks of virologic failure and all-cause deaths among older people living with HIV in Chongqing, China. AIDS Res Hum Retroviruses. 2019;35:1095\u2013102. https:\/\/doi.org\/10.1089\/aid.2019.0096.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2713_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001510","volume":"10","author":"A Mocroft","year":"2013","unstructured":"Mocroft A, Lundgren JD, Sabin ML, Monforte AD, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the collaboration of observational HIV epidemiological research Europe study (COHERE). PLoS Med. 2013;10:e1001510. https:\/\/doi.org\/10.1371\/journal.pmed.1001510.","journal-title":"PLoS Med"},{"key":"2713_CR12","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3018(24)00210-8","volume":"11","author":"FV Segala","year":"2024","unstructured":"Segala FV, Di Gennaro F, Frallonardo L, De Vita E, Petralia V, Sapienza V, et al. HIV-related outcomes among migrants living in Europe compared with the general population: a systematic review and meta-analysis. Lancet HIV. 2024;11:e833\u201342. https:\/\/doi.org\/10.1016\/S2352-3018(24)00210-8.","journal-title":"Lancet HIV"},{"key":"2713_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7110349","volume":"7","author":"S Przybyla","year":"2022","unstructured":"Przybyla S, Ashare RL, Cioffi L, Plotnik I, Shuter J, Seng EK, et al. Substance use and adherence to antiretroviral therapy among people living with HIV in the United States. Trop Med Infect Dis. 2022;7:349. https:\/\/doi.org\/10.3390\/tropicalmed7110349.","journal-title":"Trop Med Infect Dis"},{"key":"2713_CR14","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2016.14348","volume":"146","author":"KE Darling","year":"2016","unstructured":"Darling KE, Hachfeld A, Cavassini M, Kirk O, Furrer H, Wandeler G. Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. Swiss Med Wkly. 2016;146:w14348. https:\/\/doi.org\/10.4414\/smw.2016.14348.","journal-title":"Swiss Med Wkly"},{"key":"2713_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.106995","volume":"142","author":"A Mondi","year":"2024","unstructured":"Mondi A, Cozzi-Lepri A, Tavelli A, Cingolani A, Giacomelli A, Orofino G, et al. Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis \u2013 results from the ICONA cohort in Italy, 2009-2022. Int J Infect Dis. 2024;142:106995. https:\/\/doi.org\/10.1016\/j.ijid.2024.106995.","journal-title":"Int J Infect Dis"},{"key":"2713_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/cid\/ciae016","volume":"79","author":"BJ Van Welzen","year":"2024","unstructured":"Van Welzen BJ, Van Lelyveld SFL, Ter Beest G, Gisolf JH, Geerlings SE, Prins JM, et al. Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis. Clin Infect Dis. 2024;79:189\u201395. https:\/\/doi.org\/10.1093\/cid\/ciae016.","journal-title":"Clin Infect Dis"},{"key":"2713_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.14423\/SMJ.0000000000000255","volume":"108","author":"S Weissman","year":"2015","unstructured":"Weissman S, Duffus WA, Iyer M, Chakraborty H, Samantapudi AV, Albrecht H. Rural\u2013urban differences in HIV viral loads and progression to AIDS among new HIV cases. South Med J. 2015;108:180\u20138. https:\/\/doi.org\/10.14423\/SMJ.0000000000000255.","journal-title":"South Med J"},{"key":"2713_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","volume":"33","author":"AR Eckard","year":"2020","unstructured":"Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33:10\u20139. https:\/\/doi.org\/10.1097\/QCO.0000000000000616.","journal-title":"Curr Opin Infect Dis"},{"key":"2713_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jac\/dkp153","volume":"64","author":"N Sichtig","year":"2009","unstructured":"Sichtig N, Sierra S, Kaiser R, D\u00e4umer M, Reuter S, Sch\u00fclter E, et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother. 2009;64:25\u201332. https:\/\/doi.org\/10.1093\/jac\/dkp153.","journal-title":"J Antimicrob Chemother"},{"key":"2713_CR20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/infdis\/jis750","volume":"207","author":"JJ Eron","year":"2013","unstructured":"Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207:740\u20138. https:\/\/doi.org\/10.1093\/infdis\/jis750.","journal-title":"J Infect Dis"},{"key":"2713_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130118","volume":"4","author":"VF Boltz","year":"2019","unstructured":"Boltz VF, Shao W, Bale MJ, Halvas EK, Luke B, McIntyre JA, et al. Linked dual-class HIV resistance mutations are associated with treatment failure. JCI Insight. 2019;4:e130118. https:\/\/doi.org\/10.1172\/jci.insight.130118.","journal-title":"JCI Insight"},{"key":"2713_CR22","unstructured":"European centre for disease prevention and control\/WHO regional office for Europe. HIV\/AIDS surveillance in Europe 2022\u20132021 data. Stockholm: ECDC; 2022 [Internet]. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/hivaids-surveillance-europe-2022-2021-data"},{"key":"2713_CR23","unstructured":"European AIDS Clinical Society (EACS). Guidelines for the treatment of people living with HIV. Versions 6\u201311 (2011\u20132024) [Internet]. https:\/\/www.eacsociety.org\/guidelines (2025). Accessed 2 Dec 2025"},{"key":"2713_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431093","volume":"58","author":"N L\u00fcbke","year":"2015","unstructured":"L\u00fcbke N, Di Cristanziano V, Sierra S, Knops E, Sch\u00fclter E, Jensen B, et al. Proviral DNA as a target for HIV-1 resistance analysis. Intervirology. 2015;58:184\u20139. https:\/\/doi.org\/10.1159\/000431093.","journal-title":"Intervirology"},{"key":"2713_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000331999","volume":"55","author":"M Obermeier","year":"2012","unstructured":"Obermeier M, Pironti A, Berg T, Braun P, D\u00e4umer M, Eberle J, et al. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology. 2012;55:102\u20137. https:\/\/doi.org\/10.1159\/000331999.","journal-title":"Intervirology"},{"key":"2713_CR26","unstructured":"HIV-GRADE HIV-1 Resistance interpretation tool [Internet]. https:\/\/www.hiv-grade.de\/grade_new\/ (2025). Accessed 5 Dec 2025"},{"key":"2713_CR27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1056\/NEJMc1806554","volume":"381","author":"N L\u00fcbke","year":"2019","unstructured":"L\u00fcbke N, Jensen B, H\u00fcttig F, Feldt T, Walker A, Thielen A, et al. Failure of dolutegravir first-line ART with selection of virus carrying R263K and G118R. N Engl J Med. 2019;381:887\u20139. https:\/\/doi.org\/10.1056\/NEJMc1806554.","journal-title":"N Engl J Med"},{"key":"2713_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","volume":"19","author":"M Aboud","year":"2019","unstructured":"Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19:253\u201364. https:\/\/doi.org\/10.1016\/S1473-3099(19)30036-2.","journal-title":"Lancet Infect Dis"},{"key":"2713_CR29","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/cid\/ciw416","volume":"63","author":"AJ Low","year":"2016","unstructured":"Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;63:1094\u2013104. https:\/\/doi.org\/10.1093\/cid\/ciw416.","journal-title":"Clin Infect Dis"},{"key":"2713_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/v16030399","volume":"16","author":"C Chu","year":"2024","unstructured":"Chu C, Tao K, Kouamou V, Avalos A, Scott J, Grant PM, et al. Prevalence of emergent dolutegravir resistance mutations in people living with HIV: a rapid scoping review. Viruses. 2024;16:399. https:\/\/doi.org\/10.3390\/v16030399.","journal-title":"Viruses"},{"key":"2713_CR31","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/ciad020","volume":"76","author":"ET Overton","year":"2023","unstructured":"Overton ET, Richmond G, Rizzardini G, Thalme A, Girard P-M, Wong A, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023;76:1646\u201354. https:\/\/doi.org\/10.1093\/cid\/ciad020.","journal-title":"Clin Infect Dis"},{"key":"2713_CR32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","volume":"35","author":"AG Cutrell","year":"2021","unstructured":"Cutrell AG, Schapiro JM, Perno CF, Kuritzkes DR, Quercia R, Patel P, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. 2021;35:1333\u201342. https:\/\/doi.org\/10.1097\/QAD.0000000000002883.","journal-title":"AIDS"},{"key":"2713_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006895","volume":"14","author":"D K\u00fchnert","year":"2018","unstructured":"K\u00fchnert D, Kouyos R, Shirreff G, Pe\u010derska J, Scherrer AU, B\u00f6ni J, et al. Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. PLOS Pathog. 2018;14:e1006895. https:\/\/doi.org\/10.1371\/journal.ppat.1006895.","journal-title":"PLOS Pathog"},{"key":"2713_CR34","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(17)32299-7.","journal-title":"Lancet"},{"key":"2713_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013016","volume":"97","author":"K Jacobson","year":"2018","unstructured":"Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-na\u00efve human immunodeficiency virus\u2013infected patients compared to non-nucleoside and protease inhibitor\u2013based regimens in a real-world clinical setting: a retrospective cohort study. Medicine (Baltimore). 2018;97:e13016. https:\/\/doi.org\/10.1097\/MD.0000000000013016.","journal-title":"Medicine (Baltimore)"},{"key":"2713_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/HIV.S406372","volume":"15","author":"D Melak","year":"2023","unstructured":"Melak D, Wedajo S, Dewau R. Time to viral re-suppression and its predictors among adults on second-line antiretroviral therapy in south wollo zone public hospitals: stratified Cox model. HIV AIDS Auckl NZ. 2023;15:411\u201321. https:\/\/doi.org\/10.2147\/HIV.S406372.","journal-title":"HIV AIDS Auckl NZ"},{"key":"2713_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25485","volume":"23","author":"S Novelli","year":"2020","unstructured":"Novelli S, Delobel P, Bouchaud O, Avettand\u2010Fenoel V, Fialaire P, Cabi\u00e9 A, et al. Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV\u20101 infection: results from a longitudinal study in the French ANRS Primo cohort. J Int AIDS Soc. 2020;23:e25485. https:\/\/doi.org\/10.1002\/jia2.25485.","journal-title":"J Int AIDS Soc"},{"key":"2713_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/aid.2019.0193","volume":"36","author":"JKC Law","year":"2020","unstructured":"Law JKC, Butler LT, Hamill MM. Predictors of discontinuation of efavirenz as treatment for HIV, due to neuropsychiatric side effects, in a multi-ethnic sample in the United Kingdom. AIDS Res Hum Retroviruses. 2020;36:459\u201366. https:\/\/doi.org\/10.1089\/aid.2019.0193.","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02713-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02713-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02713-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:54:18Z","timestamp":1774551258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02713-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2713"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02713-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7722983\/v1","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Ethics Committee of Heinrich Heine University D\u00fcsseldorf (Study No. 4862) and conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent prior to inclusion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}